|Bid||77.77 x 100|
|Ask||78.17 x 100|
|Day's Range||77.70 - 79.26|
|52 Week Range||63.68 - 99.14|
|PE Ratio (TTM)||-3.30|
|Dividend & Yield||0.64 (0.82%)|
|1y Target Est||N/A|
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
Perrigo (PRGO) got a big lift off last week’s second quarter financial results. The stock price had a 16% one-day surge after the drug maker posted quarterly financial results that beat estimates and raised its guidance. It offered a stark contradiction to other specialty drug makers, namely the dismal results posted earlier this month by Teva Pharmaceutical Industries (TEVA).
Q2 2017 Perrigo Company PLC Earnings Call